Literature DB >> 9511065

Synergic activity of vancomycin-quinupristin/dalfopristin combination against Enterococcus faecium.

V Lorian1, F Fernandes.   

Abstract

Clinical specimens were cultured, and the strains identified by the Vitek system as Enterococcus faecium were characterized by their DNA. The MIC vancomycin, quinupristin/dalfopristin and teicoplanin for each isolate was determined. Ten vancomycin-sensitive and ten vancomycin-resistant strains of E. faecium were tested. Quinupristin/dalfopristin at 0.25 x MIC and vancomycin at 0.5 x MIC separately as well as in combination were added to Trypticase Soy Broth tubes inoculated with a 24 h culture. The results obtained by determining cfu at 2, 4, 8, 12 and 24 h indicated that the combination of subinhibitory concentrations of quinupristin/dalfopristin plus vancomycin produced after 24 h, in vancomycin-resistant strains, a consistent degree of synergy. Synergy was observed up to only 12 h when similar combinations were employed for vancomycin-sensitive strains. Vancomycin-sensitive strains tended to be slightly less susceptible to quinupristin/dalfopristin than vancomycin-resistant strains.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9511065     DOI: 10.1093/jac/39.suppl_1.63

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

Review 1.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Quinupristin/dalfopristin: the first available macrolide-lincosamide-streptogramin antibiotic.

Authors:  C Gurk-Turner
Journal:  Proc (Bayl Univ Med Cent)       Date:  2000-01

3.  Pharmacokinetics of quinupristin/ dalfopristin in patients with severe chronic renal insufficiency.

Authors:  P Chevalier; J Rey; O Pasquier; V Leclerc; J C Baguet; A Meyrier; N Harding; G Montay
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

4.  In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model.

Authors:  George P Allen; Raymond Cha; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 5.  Streptogramins and their potential role in geriatric medicine.

Authors:  B M Lomaestro; L L Briceland
Journal:  Drugs Aging       Date:  1998-12       Impact factor: 3.923

6.  Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci.

Authors:  G M Eliopoulos; C B Wennersten
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 7.  Endophthalmitis caused by Gram-positive organisms with reduced vancomycin susceptibility: literature review and options for treatment.

Authors:  Nidhi Relhan; Thomas A Albini; Avinash Pathengay; Ajay E Kuriyan; Darlene Miller; Harry W Flynn
Journal:  Br J Ophthalmol       Date:  2015-12-23       Impact factor: 4.638

8.  Quinupristin/dalfopristin in Staphylococcus aureus endophthalmitis: a case report.

Authors:  Sergio E Hernandez-Da Mota
Journal:  J Med Case Rep       Date:  2011-03-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.